Search - tctmd.com

Displaying 161 - 180 of 423

Sort: Relevancy | Date

News Conference News TCT 2017

Compared With Provisional Stenting, Double-Kissing Crush Technique Reduces Left Main Disease Events at 1 Year

Yael L. Maxwell

October 30, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Conference News ESC 2017

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

Shelley Wood

August 30, 2017

News Daily News

Boston Scientific Scraps Biodegradable Scaffold Program

Michael O'Riordan

August 01, 2017

News Industry News

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

July 28, 2017

News Daily News

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Shelley Wood

July 21, 2017

News Daily News

Full Metal Jacket Approach Yields ‘Acceptable’ Long-term Outcomes in CTOs

Yael L. Maxwell

June 30, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Conference News EuroPCR 2017

Slimmest Stent to Date Looks Promising in Small Study

Shelley Wood

May 19, 2017

News Conference News EuroPCR 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Michael O'Riordan

May 19, 2017

News Industry News

Medtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year

May 18, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Conference News SCAI 2017

Bioresorbable Scaffolds: Where Do We Go From Here?

L.A. McKeown

May 15, 2017

News Daily News

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

Yael L. Maxwell

April 17, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

Advertisement

Compared With Provisional Stenting, Double-Kissing Crush Technique Reduces Left Main Disease Events at 1 Year

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

Boston Scientific Scraps Biodegradable Scaffold Program

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Full Metal Jacket Approach Yields ‘Acceptable’ Long-term Outcomes in CTOs

TCTMD’s Top 10 Most Popular Stories for May 2017

Slimmest Stent to Date Looks Promising in Small Study

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Medtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Bioresorbable Scaffolds: Where Do We Go From Here?

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content